Timing is everything: study links treatment delays to colorectal cancer survival
NCT ID NCT04916054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 227 people with colorectal cancer that had spread to the lining of the belly. Researchers wanted to see if waiting longer between chemotherapy and surgery affected how long patients lived without the cancer coming back. The goal is to find the best timing for treatments to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
227 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Mar 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with a surgery for peritoneal carcinosis of colorectal origin between 2007 and 2019 * Patients from the Institut de cancérologie de l'Ouest and the CHU of Lyon for the study period 2007-2016 * Patients included in the BIG-RENAPE network between 2016 and 2019
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age \>18 years 2. Histological evidence of peritoneal metastases 3. Primary colorectal cancer 4. Surgical cytoreduction CC0 or CC1 Exclusion Criteria: 1. Patient who has not received at least 3 courses of pre and/or post cytoreduction chemotherapy 2. Primitive appendicitis 3. Unknown primitive 4. Patient with incomplete CC2 and/or palliative surgery 5. Patient opposed to the use of their data for research. 6. Isolated local pelvic recurrence. 7. Extraperitoneal metastases not resected or destroyed before or during cytoreduction. 8. Patient opposed to the use of his/her data for research purposes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colo-rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU LYON
Lyon, France
-
Institut de Cancerologie de L'Ouest
Saint-Herblain, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a platform trial match the right drug combo to each tumor?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a registry make endoscopic procedures safer and more effective?
- Can extra weight complicate colorectal surgery? a new study investigates
- A new clue in the fight against colorectal cancer recurrence?